参考文献/References:
[1] Yin ET,Wessler S,Stoll PJ. Biological properties of the naturally occurring plasma inhibitor to activated factor X[J]. J Biol Chem,1971,246(11):3703-3711.
[2] Walenga JM,Jeske WP,Bara L,et al. Biochemical and pharmacologic rationale for the development of a synthetic pentasaccharide[J]. Thromb Res,1997,86(1):1-36.
[3] Bounameaux H,Perneger T. Fondapariunx:a new synthetic pentasaccharide for thrombosis prevention[J]. Lancet,2002,359(9319):1710-1711.
[4] Olson ST, Bj?rk I,Sheffer R,et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement[J].?J Biol Chem,1992,267(18):12528-12538.
[5] Lassen MR,Bauer KA,Eriksson BI,et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip replacement surgery:a randomized double blind comparison[J]. Lancet,2002,359(9319):1715-1720.
[6] Lane DA,Lip GY. Patient’s values and preferences for stroke prevention in atrial fibrillation:balancing stroke and bleeding risk with oral anticoagulation[J].?Thromb Haemost,2014,111(3):381-383.?
[7] Lau YC,Brown RA,Lip GY. Fondaparinux in atrial fibrillation—Old dog,new tricks?[J].?Arch Cardiovasc Dis,2015,108(2):85-87.
[8] Rosa GM,Parodi A,Dorighi U,et al.?Left atrial thrombosis in an anticoagulated patient after bioprosthetic valve replacement:report of a case[J].?World J Clin Cases,2014,2(1):20-23
[9] Apostolakis S,Sullivan RM,Olshansky B,et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin:the SAMe-TT2R? score[J].?Chest,2013,144(5):1555-1563.
[10] Cohen A,Stellbrink C,le Heuzey JY,et al. SAfety of Fondaparinux in transoesophageal echocardiography-guided Electric cardioversion of Atrial Fibrillation(SAFE-AF) study:a pilot study[J].?Arch Cardiovasc Dis,2015,108(2):122-131.
[11] Stellbrink C,Nixdorff U,Hofmann T,et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation:the Anticoagulation in Cardioversion using Enoxaparin(ACE) trial[J].?Circulation,2004,109(8):997-1003.
[12] Gulley D,Teal E,Suvannasankha A,et al. Deep vein thrombosis and pulmonary embolism in cirrhosis patients[J]. Dig Dis Sci,2008,53(11):3012-3017.
[13] Intagliata NM,Caldwell SH,Tripodi A. Diagnosis,development,and treatment of portal vein thrombosis in patients with and without cirrhosis[J].?Gastroenterology,2019,156(6):1582-1599.
[14] Senzolo M,Piano S,Shalaby S,et al. Comparison of fondaparinux and low-molecular-weight heparin in the treatment of portal vein thrombosis in cirrhosis[J].?Am J Med,2021,134(10):1278-1285.?
[15] Zhang ZH,Zhang JW,He P,et al. Fondaparinux is effective for acute portal vein thrombosis in decompensated cirrhotic patients[J].?Medicine(Baltimore),2017,96(42):e8256.
[16] Russo V,Bottino R,Carbone A,et al. COVID-19 and heart:from clinical features to pharmacological implications[J]. J Clin Med,2020,9(6):1944.
[17] Scudiero F,Silverio A,di Maio M,et al. Pulmonary embolism in COVID-19 patients:prevalence,predictors and clinical outcome[J]. Thromb Res,2021,198:34-39.
[18] Klok FA,Kruip MJHA,van der Meer NJM,et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19[J].?Thromb Res,2020,191:145-147.
[19] Cattaneo M,Bertinato EM,Birocchi S,et al. Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified?[J].?Thromb Haemost,2020,120(8):1230-1232.
[20] di Micco P,di Micco G,Russo V,et al. Blood targets of adjuvant drugs against COVID-19[J]. J Blood Med,2020,11:237-241.
[21] Tiwari V,Beer JC,Sankaranarayanan NV,et al. Discovering small-molecule therapeutics against SARS-CoV-2[J]. Drug Discov Today,2020,25(8):1535-1544.
[22] Cardillo G,Viggiano GV,Russo V,et al. Antithrombotic and anti-inflammatory effects of fondaparinux and enoxaparin in hospitalized COVID-19 patients:the FONDENOXAVID study[J].?J Blood Med,2021,12:69-75.
[23] Russo V,Cardillo G,Viggiano GV,et al. Fondaparinux use in patients with COVID-19:a preliminary multicenter real-world experience[J].?J Cardiovasc Pharmacol,2020,76(4):369-371.
[24] Kosior DA,Undas A,Kope? G,et al. Guidance for anticoagulation management in venous thromboembolism during the coronavirus disease 2019 pandemic in Poland:an expert opinion of the Section on Pulmonary Circulation of the Polish Cardiac Society[J].?Kardiol Pol,2020,78(6):642-646.
[25] Lyman GH,Carrier M,Ay C,et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism:prevention and treatment in patients with cancer [J].?Blood Adv,2021,5(4):927-974.
[26] Mehta SR,Granger CB,Eikelboom JW,et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention:results from the OASIS-5 trial[J].?J Am Coll Cardiol,2007,50(18):1742-1751.
[27] Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators,Yusuf S,Mehta SR,et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes[J].?N Engl J Med,2006,354(14):1464-1476.
[28] Anderson JA,Hirsh J,Yusuf S,et al. Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic syndromes (OASIS)-5 trial[J].?J Thromb Haemost,2010,8(2):243-249.
[29] Almendro-Delia M,Izquierdo-Bajo ?,Madrona-Jiménez L,et al. Fondaparinux versus enoxaparin in the contemporary management of non-ST-elevation acute coronary syndromes. Insights from a multicenter registry[J].?Int J Cardiol,2021,332:29-34.
[30] Yusuf S,Mehta SR,Chrolavicius S,et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction:the OASIS-6 randomized trial[J].?JAMA,2006,295(13):1519-1530.
[31] Bundhun PK,Shaik M,Yuan J. Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome:a systematic review and meta-analysis[J].?BMC Cardiovasc Disord,2017,17(1):116.
[32] Soeiro AM,Silva PG,Roque EA,et al. Fondaparinux versus enoxaparin - Which is the best anticoagulant for acute coronary syndrome? - Brazilian registry data[J].?Arq Bras Cardiol,2016,107(3):239-244.
[33] Bhatt VR,Aryal MR,Shrestha R,et al. Fondaparinux-associated heparin-induced thrombocytopenia[J].?Eur J Haematol,2013,91(5):437-441.
[34] Prince M,Wenham T. Heparin-induced thrombocytopaenia[J].?Postgrad Med J,2018, 94(1114):453-457.?
[35] Linkins LA. Heparin induced thrombocytopenia[J].?BMJ,2015,350:g7566.
[36] Guyatt GH,Aki EA,Crowther M,et al. Executive summary:antithrombotic therapy and prevention of thrombosis,9th ed.American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest,2012,141(2 suppl):7S-47S.
[37] Chaudhary RK,Khanal N,Giri S,et al. Emerging therapy options in heparin-induced thrombocytopenia[J]. Cardiovasc Hematol Agents Med Chem,2014,12(1):50-58.
[38] Kelton JG,Arnold DM,Bates SM. Nonheparin anticoagulants for heparin-induced thrombocytopenia[J]. N Engl J Med,2013,368(8):737-744.
[39] Badger NO. Fondaparinux(Arixtra(R)),a safe alternative for the treatment of patients with heparin-induced thrombocytopenia?[J].?J Pharm Pract,2010,23(3):235-238.?
[40] Cegarra-Sanmartín V,González-Rodríguez R,Paniagua-Iglesias P,et al. Fondaparinux as a safe alternative for managing heparin-induced thrombocytopenia in postoperative cardiac surgery patients[J].?J Cardiothorac Vasc Anesth,2014,28(4):1008-1012.
[41] Dulicek P,Ivanova E,Kostal M,et al. Heparin-induced thrombocytopenia treated with fondaparinux:single center experience[J].?Int Angiol,2020,39(1):76-81.
[42] Snodgrass MN,Shields J,Rai H. Efficacy and safety of fondaparinux in patients with suspected heparin-induced thrombocytopenia[J].?Clin Appl Thromb Hemost,2016,22(8):712-717.?
[43] Cuker A,Arepally GM,Chong BH,et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism:heparin-induced thrombocytopenia[J].?Blood Adv,2018,2(22):3360-3392.
[44] Linkins LA,Dans AL,Moores LK,et al. Treatment and prevention of heparin-induced thrombocytopenia:Antithrombotic Therapy and Prevention of Thrombosis,9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].?Chest,2012,141(2 suppl):e495S-e530S.